Selected article for: "cardiac tissue and SARS entry"

Author: D’Onofrio, Nunzia; Scisciola, Lucia; Sardu, Celestino; Trotta, Maria Consiglia; De Feo, Marisa; Maiello, Ciro; Mascolo, Pasquale; De Micco, Francesco; Turriziani, Fabrizio; Municinò, Emilia; Monetti, Pasquale; Lombardi, Antonio; Napolitano, Maria Gaetana; Marino, Federica Zito; Ronchi, Andrea; Grimaldi, Vincenzo; Hermenean, Anca; Rizzo, Maria Rosaria; Barbieri, Michelangela; Franco, Renato; Campobasso, Carlo Pietro; Napoli, Claudio; Municinò, Maurizio; Paolisso, Giuseppe; Balestrieri, Maria Luisa; Marfella, Raffaele
Title: Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte
  • Cord-id: t72ymsei
  • Document date: 2021_5_7
  • ID: t72ymsei
    Snippet: RATIONALE: About 50% of hospitalized coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM) developed myocardial damage. The mechanisms of direct SARS-CoV-2 cardiomyocyte infection include viral invasion via ACE2-Spike glycoprotein-binding. In DM patients, the impact of glycation of ACE2 on cardiomyocyte invasion by SARS-CoV-2 can be of high importance. OBJECTIVE: To evaluate the presence of SARS-CoV-2 in cardiomyocytes from heart autopsy of DM cases compared to Non-DM; to inve
    Document: RATIONALE: About 50% of hospitalized coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM) developed myocardial damage. The mechanisms of direct SARS-CoV-2 cardiomyocyte infection include viral invasion via ACE2-Spike glycoprotein-binding. In DM patients, the impact of glycation of ACE2 on cardiomyocyte invasion by SARS-CoV-2 can be of high importance. OBJECTIVE: To evaluate the presence of SARS-CoV-2 in cardiomyocytes from heart autopsy of DM cases compared to Non-DM; to investigate the role of DM in SARS-COV-2 entry in cardiomyocytes. METHODS AND RESULTS: We evaluated consecutive autopsy cases, deceased for COVID-19, from Italy between Apr 30, 2020 and Jan 18, 2021. We evaluated SARS-CoV-2 in cardiomyocytes, expression of ACE2 (total and glycosylated form), and transmembrane protease serine protease-2 (TMPRSS2) protein. In order to study the role of diabetes on cardiomyocyte alterations, independently of COVID-19, we investigated ACE2, glycosylated ACE2, and TMPRSS2 proteins in cardiomyocytes from DM and Non-DM explanted-hearts. Finally, to investigate the effects of DM on ACE2 protein modification, an in vitro glycation study of recombinant human ACE2 (hACE2) was performed to evaluate the effects on binding to SARS-CoV-2 Spike protein. The authors included cardiac tissue from 97 autopsies. DM was diagnosed in 37 patients (38%). Fourth-seven out of 97 autopsies (48%) had SARS-CoV-2 RNA in cardiomyocytes. Thirty out of 37 DM autopsy cases (81%) and 17 out of 60 Non-DM autopsy cases (28%) had SARS-CoV-2 RNA in cardiomyocytes. Total ACE2, glycosylated ACE2, and TMPRSS2 protein expressions were higher in cardiomyocytes from autopsied and explanted hearts of DM than Non-DM. In vitro exposure of monomeric hACE2 to 120 mM glucose for 12 days led to non-enzymatic glycation of four lysine residues in the neck domain affecting the protein oligomerization. CONCLUSIONS: The upregulation of ACE2 expression (total and glycosylated forms) in DM cardiomyocytes, along with non-enzymatic glycation, could increase the susceptibility to COVID-19 infection in DM patients by favouring the cellular entry of SARS-CoV2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01286-7.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adaptive immunity impaired innate: 1, 2, 3
    • acute respiratory syndrome and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • acute respiratory syndrome and local ethic committee: 1
    • acute respiratory syndrome and long term effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and low percentage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and lower apparent: 1, 2
    • acute respiratory syndrome and lysine residue: 1, 2, 3, 4, 5
    • acute respiratory syndrome and lysis buffer: 1, 2, 3
    • adaptive immunity and low percentage: 1, 2, 3